2026 Q1 -tulosraportti
15 päivää sitten
‧43 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 52 | NON | AVA | ||
| 50 | CAR | AVA | ||
| 1 442 | NRD | AVA | ||
| 340 | NRD | AVA | ||
| 272 | NON | AVA |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·10 t sitten · MuokattuI have sent some questions to Curasight based on the timeline from the TD Cowen conference in March. Q. concern the capital requirement wish for 2027, the company's 'catalysts' on the timeline (picture), M&A / Nasdaq elaboration, confirmation of the number of patients for uTREAT Phase 2 (60pers) and Basket trial Phase 1 (up to six persons per indication) etc. The timeline shows a clear strategy, where there is an opportunity to go several ways (but where the highway is called acquisition). I will follow up with answers if I hear from them.·9 t sittenNb^2: Also interesting that uTRACE Phase 2 is planned to be conducted in both EU and USA. And Nasdaq listing: I wonder if it will be an ADR like Novo Nordisk?
·2 päivää sitten🚀 Will a share issue of DKK 20-30 million strengthen the negotiation position? No, Big Pharma knows what it takes to develop a radiopharma platform. They can immediately see through the intention behind a small share issue. The most interesting thing is actually not the share issue, but what Ulrich said about the capital needs in H2: "...of course we will ensure, when we talk about new studies and other things, that there is an agreement behind it of one kind or another, that can carry it through." He is not talking about capital raising or financing, but about an agreement. If the plan was to further develop the platform alone, the focus would be on capital, organization, and study plans. Not on the fact that there ”of course” must be an agreement behind new studies. Ulrich's statement does not say whether the agreement will be an acquisition or a partnership, but it says something important about the strategic direction the management has chosen. There are really only two possibilities: 💎 1. Acquisition 💎 2. Partnership And precisely for this reason, the discussion about a share issue of DKK 20-30 million seems somewhat uninteresting. The question is no longer whether the platform should be further developed alone, but which of the 2 strategies the management has chosen. Here I will refer to my post on June 1, where I argued that an acquisition with 90-95% probability is most realistic. I still believe that we will see 2 reratings of the case. The first with uTREAT topline in Q3 (my guess is by mid-July at the latest). The second with an acquisition (or a partnership agreement), which will be the really big one. With an acquisition, all asymmetry in the case disappears. 🔥 The recent stock fluctuations after readout absolutely change NOTHING about the case, on the contrary, as uncertainty has been removed. The interesting thing is data and the strategic clarification. Readout: it works! Topline: how well does it work? Data is King - we need to see it! ⚡
·2 päivää sittenIt took the top off a very aggressive price jump created by rampant hype. The news was no better than what was already largely priced in. It is still up 75% for the year, people are hard to please. Interesting if it finds a bottom here, needs to go down a few more kroner or if someone manages to pump enough hype back into it before it settles completely. Exciting case for the year - it can become exciting again in 2 hours - but it can also become several weeks, very, very, very long weeks for 'the case needs to be recalibrated, repriced and re-evaluated by the biggest houses and the BP elite' in 2 sec. It's going its way, they are executing, it's running fine - personally I think they have missed a golden opportunity to raise money in the here and now zone 18-22kr; even if it had disappointed people who were buying into the rise....
·2 päivää sittenPatience!, close your eyes to the price, enjoy the football World Cup, this will come eventually:-)·2 päivää sittenThat's how the stock market works, use it for your own gain my friend;-)
·2 päivää sittenAs far as I know, there are rules for such things on the stock market.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
15 päivää sitten
‧43 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·10 t sitten · MuokattuI have sent some questions to Curasight based on the timeline from the TD Cowen conference in March. Q. concern the capital requirement wish for 2027, the company's 'catalysts' on the timeline (picture), M&A / Nasdaq elaboration, confirmation of the number of patients for uTREAT Phase 2 (60pers) and Basket trial Phase 1 (up to six persons per indication) etc. The timeline shows a clear strategy, where there is an opportunity to go several ways (but where the highway is called acquisition). I will follow up with answers if I hear from them.·9 t sittenNb^2: Also interesting that uTRACE Phase 2 is planned to be conducted in both EU and USA. And Nasdaq listing: I wonder if it will be an ADR like Novo Nordisk?
- ·2 päivää sitten🚀 Will a share issue of DKK 20-30 million strengthen the negotiation position? No, Big Pharma knows what it takes to develop a radiopharma platform. They can immediately see through the intention behind a small share issue. The most interesting thing is actually not the share issue, but what Ulrich said about the capital needs in H2: "...of course we will ensure, when we talk about new studies and other things, that there is an agreement behind it of one kind or another, that can carry it through." He is not talking about capital raising or financing, but about an agreement. If the plan was to further develop the platform alone, the focus would be on capital, organization, and study plans. Not on the fact that there ”of course” must be an agreement behind new studies. Ulrich's statement does not say whether the agreement will be an acquisition or a partnership, but it says something important about the strategic direction the management has chosen. There are really only two possibilities: 💎 1. Acquisition 💎 2. Partnership And precisely for this reason, the discussion about a share issue of DKK 20-30 million seems somewhat uninteresting. The question is no longer whether the platform should be further developed alone, but which of the 2 strategies the management has chosen. Here I will refer to my post on June 1, where I argued that an acquisition with 90-95% probability is most realistic. I still believe that we will see 2 reratings of the case. The first with uTREAT topline in Q3 (my guess is by mid-July at the latest). The second with an acquisition (or a partnership agreement), which will be the really big one. With an acquisition, all asymmetry in the case disappears. 🔥 The recent stock fluctuations after readout absolutely change NOTHING about the case, on the contrary, as uncertainty has been removed. The interesting thing is data and the strategic clarification. Readout: it works! Topline: how well does it work? Data is King - we need to see it! ⚡
- ·2 päivää sittenIt took the top off a very aggressive price jump created by rampant hype. The news was no better than what was already largely priced in. It is still up 75% for the year, people are hard to please. Interesting if it finds a bottom here, needs to go down a few more kroner or if someone manages to pump enough hype back into it before it settles completely. Exciting case for the year - it can become exciting again in 2 hours - but it can also become several weeks, very, very, very long weeks for 'the case needs to be recalibrated, repriced and re-evaluated by the biggest houses and the BP elite' in 2 sec. It's going its way, they are executing, it's running fine - personally I think they have missed a golden opportunity to raise money in the here and now zone 18-22kr; even if it had disappointed people who were buying into the rise....
- ·2 päivää sittenPatience!, close your eyes to the price, enjoy the football World Cup, this will come eventually:-)·2 päivää sittenThat's how the stock market works, use it for your own gain my friend;-)·2 päivää sittenAs far as I know, there are rules for such things on the stock market.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 52 | NON | AVA | ||
| 50 | CAR | AVA | ||
| 1 442 | NRD | AVA | ||
| 340 | NRD | AVA | ||
| 272 | NON | AVA |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
2026 Q1 -tulosraportti
15 päivää sitten
‧43 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·10 t sitten · MuokattuI have sent some questions to Curasight based on the timeline from the TD Cowen conference in March. Q. concern the capital requirement wish for 2027, the company's 'catalysts' on the timeline (picture), M&A / Nasdaq elaboration, confirmation of the number of patients for uTREAT Phase 2 (60pers) and Basket trial Phase 1 (up to six persons per indication) etc. The timeline shows a clear strategy, where there is an opportunity to go several ways (but where the highway is called acquisition). I will follow up with answers if I hear from them.·9 t sittenNb^2: Also interesting that uTRACE Phase 2 is planned to be conducted in both EU and USA. And Nasdaq listing: I wonder if it will be an ADR like Novo Nordisk?
- ·2 päivää sitten🚀 Will a share issue of DKK 20-30 million strengthen the negotiation position? No, Big Pharma knows what it takes to develop a radiopharma platform. They can immediately see through the intention behind a small share issue. The most interesting thing is actually not the share issue, but what Ulrich said about the capital needs in H2: "...of course we will ensure, when we talk about new studies and other things, that there is an agreement behind it of one kind or another, that can carry it through." He is not talking about capital raising or financing, but about an agreement. If the plan was to further develop the platform alone, the focus would be on capital, organization, and study plans. Not on the fact that there ”of course” must be an agreement behind new studies. Ulrich's statement does not say whether the agreement will be an acquisition or a partnership, but it says something important about the strategic direction the management has chosen. There are really only two possibilities: 💎 1. Acquisition 💎 2. Partnership And precisely for this reason, the discussion about a share issue of DKK 20-30 million seems somewhat uninteresting. The question is no longer whether the platform should be further developed alone, but which of the 2 strategies the management has chosen. Here I will refer to my post on June 1, where I argued that an acquisition with 90-95% probability is most realistic. I still believe that we will see 2 reratings of the case. The first with uTREAT topline in Q3 (my guess is by mid-July at the latest). The second with an acquisition (or a partnership agreement), which will be the really big one. With an acquisition, all asymmetry in the case disappears. 🔥 The recent stock fluctuations after readout absolutely change NOTHING about the case, on the contrary, as uncertainty has been removed. The interesting thing is data and the strategic clarification. Readout: it works! Topline: how well does it work? Data is King - we need to see it! ⚡
- ·2 päivää sittenIt took the top off a very aggressive price jump created by rampant hype. The news was no better than what was already largely priced in. It is still up 75% for the year, people are hard to please. Interesting if it finds a bottom here, needs to go down a few more kroner or if someone manages to pump enough hype back into it before it settles completely. Exciting case for the year - it can become exciting again in 2 hours - but it can also become several weeks, very, very, very long weeks for 'the case needs to be recalibrated, repriced and re-evaluated by the biggest houses and the BP elite' in 2 sec. It's going its way, they are executing, it's running fine - personally I think they have missed a golden opportunity to raise money in the here and now zone 18-22kr; even if it had disappointed people who were buying into the rise....
- ·2 päivää sittenPatience!, close your eyes to the price, enjoy the football World Cup, this will come eventually:-)·2 päivää sittenThat's how the stock market works, use it for your own gain my friend;-)·2 päivää sittenAs far as I know, there are rules for such things on the stock market.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 52 | NON | AVA | ||
| 50 | CAR | AVA | ||
| 1 442 | NRD | AVA | ||
| 340 | NRD | AVA | ||
| 272 | NON | AVA |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt